doi: 10.1111/jocn.17565.
- PMID: 39603980
- DOI: 10.1111/jocn.17565
Abstract
Background: People with HIV have a higher risk of developing non-AIDS-defining cancers in older age, leading to a significant population living with two conditions, HIV and cancer. There is an increasing interest in cannabis use for symptom management in people with chronic conditions; in 2023, the American Nurses Association officially recognised cannabis nursing as a specialty nursing practice focusing on the care of individuals seeking education/guidance in the therapeutic use of cannabis, supporting the urgency of its research. However, the scientific literature lacks a synthesised review in the focused populations.
Aim: To explore observational research on cannabis use for symptom management among people with HIV and/or cancer and identify gaps in current knowledge to inform future research and policy development.
Methods: Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Extension for Scoping Reviews (PRISMA-ScR) checklist, a literature search of relevant articles was conducted in the databases PubMed (n = 552), PsycInfo (n = 204), CINAHL (n = 164) and Embase (n = 976). Upon screening 1738 articles, 142 were identified for full-text review and 51 were retained for data extraction.
Results: There were more studies evaluating cannabis use among people with cancer than with HIV and no studies among people living with comorbid HIV and cancer. Most studies were cross-sectional with limited metrics on the perceived effectiveness and safety of cannabis use for symptom management and its dosing/mode of delivery for reducing symptoms. While studies focused on cannabis therapy under the provision of healthcare providers, individuals reported obtaining information about cannabis from friends/family/the Internet.
Implications for cannabis nursing: This body of research could be strengthened by rigorous longitudinal study designs to build causal relationships on the therapeutic effects of cannabis use and the inclusion of reliable and valid symptom assessment measures over time, which facilitates developing clinical practice guidance and policymaking in cannabis nursing.
Patient or public contribution: No patient or public contribution.
Keywords: HIV, cancer, cannabinoids, cannabis, cannabis nursing, medical marijuana, scoping review
© 2024 John Wiley & Sons Ltd.
References
-
- American Nurses Association (ANA). 2023. “ANA Officially Recognizes Cannabis Nursing as a Specialty Nursing Practice.” https://www.nursingworld.org/news/news‐releases/2023/ana‐officially‐reco….
-
- Anderson, S. P., D. M. Zylla, D. M. McGriff, and T. J. Arneson. 2019. “Impact of Medical Cannabis on Patient‐Reported Symptoms for Patients With Cancer Enrolled in Minnesota’s Medical Cannabis Program.” Journal of Oncology Practice/American Society of Clinical Oncology 15, no. 4: e338–e345. https://doi.org/10.1200/jop.18.00562.
-
- Aviram, J., G. M. Lewitus, Y. Vysotski, et al. 2020. “Short‐Term Medical Cannabis Treatment Regimens Produced Beneficial Effects Among Palliative Cancer Patients.” Pharmaceuticals 13, no. 12: 435. https://doi.org/10.3390/ph13120435.
-
- Bar‐Lev Schleider, L., R. Mechoulam, I. Sikorin, T. Naftali, and V. Novack. 2022. “Adherence, Safety, and Effectiveness of Medical Cannabis and Epidemiological Characteristics of the Patient Population: A Prospective Study.” Frontiers in Medicine 9: 827849. https://doi.org/10.3389/fmed.2022.827849.
-
- Becker, W. C., Y. Li, E. C. Caniglia, et al. 2022. “Cannabis Use, Pain Interference, and Prescription Opioid Receipt Among Persons With HIV: A Target Trial Emulation Study.” AIDS Care 34, no. 4: 469–477. https://doi.org/10.1080/09540121.2021.1944597.
